Literature DB >> 26825802

Long-term results of one staged multilevel surgery with tongue suspension surgery or one level palatal surgery for treatment of moderate and severe obstructive sleep apnea.

Alper Yüksel1,2, Kadriye Serife Ugur3, Gultekin Kizilbulut4, Nebil Ark3, Hanifi Kurtaran3, Mesut Kaya3, Mehmet Gunduz3.   

Abstract

UNLABELLED: The objective of this study is to evaluate and compare the long-term efficacy of the one staged multilevel surgery (MLS) with tongue suspension (TBS) surgery or one level palatal surgery for treatment of moderate and severe obstructive sleep apnea (OSA). This is a prospective cross-sectional study.
SETTING: University hospital. Thirty-three patients diagnosed as moderate to severe OSA. Patients, with ≥ 50 % retropalopharyngeal obstruction on the Müller maneuver, were treated with palatal surgeries (PS) and patients, with ≥ 50 % retropalopharyngeal obstruction on the Müller maneuver with ≥ 50 % base of the tongue collapse, were treated with palatal surgeries and tongue suspension surgery (TBS). Patients were evaluated with one night polysomnography before the surgery and 24 months after the surgery. Patients completed Epworth sleepiness scale (ESS), snoring VAS (visual analog scale) before and 24 months after the surgery. Nine-teen patients with a mean age of 46.1 ± 8.3 underwent palatal surgeries (PS) and 14 patients with a mean age of 41.4 ± 8.9 underwent PS plus TBS. Success rate in TBS+PS group was 57.1 % and in PS group was 42.1 %. In both groups total apnea-hypopnea index (AHI) values significantly decreased after 2 years (p < 0.025) but there was no statistically significant difference between TBS+PS and PS groups. Supine AHI levels were reduced statistically significant in both groups postoperatively (p < 0.025). There was not any significant difference postoperatively in non-supine AHI levels in both groups (p > 0.025). There were significant postoperative changes in ODI, AVO2, MOS, ESS, Snoring VAS values in PS group (p < 0.025). In TBS+PS group there was a significant difference postoperatively only in ODI values. Treatment of OSA patients with retropalatal or retropalatal and retroglossal obstruction, in a one staged surgery, is a safe and easy procedure. We have achieved favorable long-term outcomes in moderate-severe OSA patients undergoing both palatal surgery and tongue suspension surgery.

Entities:  

Keywords:  Apnea–hypopnea index; Obstructive sleep apnea (OSA); Snoring; Tongue base suspension

Mesh:

Year:  2016        PMID: 26825802     DOI: 10.1007/s00405-015-3813-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  A tongue suspension suture for obstructive sleep apnea and snorers.

Authors:  B T Woodson
Journal:  Otolaryngol Head Neck Surg       Date:  2001-03       Impact factor: 3.497

2.  The effect of hyoid suspension in a multilevel surgery concept for obstructive sleep apnea.

Authors:  Alexander Baisch; Joachim Theodor Maurer; Karl Hörmann
Journal:  Otolaryngol Head Neck Surg       Date:  2006-05       Impact factor: 3.497

3.  Tongue-base suspension in conjunction with uvulopalatopharyngoplasty for treatment of severe obstructive sleep apnea: long-term follow-up results.

Authors:  Eugenio Vicente; José M Marín; Santiago Carrizo; M J Naya
Journal:  Laryngoscope       Date:  2006-07       Impact factor: 3.325

4.  Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial.

Authors:  C Jenkinson; R J Davies; R Mullins; J R Stradling
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

5.  Minimally invasive tongue base surgery for obstructive sleep apnoea.

Authors:  David J Terris; Larisa D Kunda; Marie C Gonella
Journal:  J Laryngol Otol       Date:  2002-09       Impact factor: 1.469

6.  Role of the tongue base suspension suture with The Repose System bone screw in the multilevel surgical management of obstructive sleep apnea.

Authors:  Frank R Miller; Daniel Watson; David Malis
Journal:  Otolaryngol Head Neck Surg       Date:  2002-04       Impact factor: 3.497

7.  The occurrence of sleep-disordered breathing among middle-aged adults.

Authors:  T Young; M Palta; J Dempsey; J Skatrud; S Weber; S Badr
Journal:  N Engl J Med       Date:  1993-04-29       Impact factor: 91.245

8.  Anterior palatoplasty for the treatment of OSA: three-year results.

Authors:  Kenny P Pang; Raymond Tan; Puravi Puraviappan; David J Terris
Journal:  Otolaryngol Head Neck Surg       Date:  2009-08       Impact factor: 3.497

9.  Lateral pharyngoplasty: a new treatment for obstructive sleep apnea hypopnea syndrome.

Authors:  Michel B Cahali
Journal:  Laryngoscope       Date:  2003-11       Impact factor: 3.325

10.  Genioglossus advancement and hyoid suspension plus uvulopalatopharyngoplasty for severe OSAHS.

Authors:  Shan Kai Yin; Hong Liang Yi; Wen Ying Lu; Jian Guan; Hong Min Wu; Zhen Yu Cao
Journal:  Otolaryngol Head Neck Surg       Date:  2007-04       Impact factor: 3.497

View more
  3 in total

1.  Evaluation of the success of obstructive sleep apnea surgery using criteria based on long-term symptoms and incident hypertension.

Authors:  Jae Hyun Lim; Pona Park; Jee Hye Wee; January E Gelera; Kundan Kumar Shrestha; Chae-Seo Rhee; Jeong-Whun Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-02-08       Impact factor: 2.503

2.  Transoral Tongue Suspension for Obstructive Sleep Apnea-A Preliminary Study.

Authors:  Li-Jen Hsin; Yi-Chan Lee; Wan-Ni Lin; Yi-An Lu; Li-Ang Lee; Ming-Shao Tsai; Wen-Nuan Cheng; Yen-Ting Chiang; Hsueh-Yu Li
Journal:  J Clin Med       Date:  2022-08-24       Impact factor: 4.964

3.  Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.